Cipher Pharmaceuticals (CPH) -
Event summary combining transcript, slides, and related documents.
Latest events from Cipher Pharmaceuticals
- Q1 2026 saw profit surge, margin gains, and full debt repayment, supporting future growth.CPH
Q1 20268 May 2026 - Q1 revenue surged 105% to $12M, driven by Natroba and Canadian growth, with major debt repayment.CPHQ1 202523 Apr 2026
- 2025 revenue and net income surged, led by U.S. Natroba™, with debt reduction and growth initiatives.CPHQ4 202513 Mar 2026
- Natroba acquisition and MOB-015's success drive a new phase of global growth.CPHQ2 20241 Feb 2026
- Natroba acquisition doubles sales and EBITDA, driving growth and global expansion plans.CPHPlanet MicroCap Showcase: VANCOUVER 202420 Jan 2026
- Q3 revenue up 71% year-over-year, with strong margins from Natroba but lower net income.CPHQ3 202415 Jan 2026
- 2024 revenue up 58% and adjusted EBITDA up 23%, led by Natroba and Epuris growth.CPHQ4 202426 Dec 2025
- Record Q2 2025 revenue and profit growth fueled by Natroba™ and U.S. market gains.CPHQ2 202523 Nov 2025
- Q3 2025 saw strong growth, debt reduction, and expansion plans driven by Natroba.CPHQ3 202515 Nov 2025